Peterson Wealth Services Raises Position in Johnson & Johnson (NYSE:JNJ)

Peterson Wealth Services lifted its position in Johnson & Johnson (NYSE:JNJ) by 5.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 13,111 shares of the company’s stock after acquiring an additional 669 shares during the period. Peterson Wealth Services’ holdings in Johnson & Johnson were worth $1,896,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vinva Investment Management Ltd grew its stake in shares of Johnson & Johnson by 6.8% in the third quarter. Vinva Investment Management Ltd now owns 111,448 shares of the company’s stock worth $17,988,000 after acquiring an additional 7,110 shares during the last quarter. Financial Counselors Inc. increased its stake in Johnson & Johnson by 5.3% during the 3rd quarter. Financial Counselors Inc. now owns 185,093 shares of the company’s stock valued at $29,996,000 after purchasing an additional 9,309 shares in the last quarter. Oregon Pacific Wealth Management LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $949,000. Meridian Investment Counsel Inc. grew its holdings in shares of Johnson & Johnson by 19.6% during the third quarter. Meridian Investment Counsel Inc. now owns 22,629 shares of the company’s stock valued at $3,667,000 after buying an additional 3,710 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Johnson & Johnson by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 17,639,368 shares of the company’s stock worth $2,858,543,000 after acquiring an additional 102,502 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling

In other news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.16% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Leerink Partners cut their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Raymond James decreased their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Wells Fargo & Company dropped their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Bank of America dropped their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, January 23rd. Finally, Wolfe Research started coverage on Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $156.20 on Friday. The stock has a 50-day moving average price of $147.73 and a 200 day moving average price of $156.01. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The stock has a market capitalization of $376.08 billion, a P/E ratio of 23.49, a P/E/G ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.29 earnings per share. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.18%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.